Research programme: PKN3 antagonists - Silence Therapeutics/ASINEX
Latest Information Update: 14 Jul 2010
At a glance
- Originator ASINEX; Atugen
- Class RNA
- Mechanism of Action Protein kinase N3 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 12 Jul 2005 Atugen has been acquired by SR Pharma
- 09 Feb 2005 Preclinical trials in Cancer in Europe (unspecified route)